⌘K

ANCN

NASDAQ

Anchiano Therapeutics Ltd.

SectorHealth CareIndustryMajor PharmaceuticalsIPO2019

News23/Ratings0

Latest news

23 items

1861dSEC
SEC Form 8-K/A filed by Anchiano Therapeutics Ltd.
8-K/A - Chemomab Therapeutics Ltd. (0001534248) (Filer)
1862dINSIDER
SEC Form 4: Ltd. Gp Israel Orbimed was granted 288,170 units of American Depository Shares
4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
1862dINSIDER
SEC Form 4: Peter Thiel bought $0 worth of American Depositary Shares (230,536 units at $0.00)
4 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
1862dINSIDER
SEC Form 3: Peter Thiel claimed ownership of 877,973 units of American Depositary Shares
3 - Chemomab Therapeutics Ltd. (0001534248) (Issuer)
1865dPR
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing
Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”; Nasdaq: ANCN) and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that Anchiano’s shareholders voted to approve the contemplated merger with Chemomab and the issuance of AnchianoAmerican Depositary Shares (ADSs) in conn
1868dINSIDER
SEC Form 4 filed by Stanislav Polovets
4 - Anchiano Therapeutics Ltd. (0001534248) (Issuer)
1868dINSIDER
SEC Form 3 filed by Stanislav Polovets
3 - Anchiano Therapeutics Ltd. (0001534248) (Issuer)
1869dINSIDER
SEC Form 3 filed by Andrew Fine
3 - Anchiano Therapeutics Ltd. (0001534248) (Issuer)
1869dINSIDER
SEC Form 4 filed by Harris Neil Cohen
4 - Anchiano Therapeutics Ltd. (0001534248) (Issuer)
1869dINSIDER
SEC Form 3: Harris Neil Cohen claimed ownership of 62,110 units of Ordinary Shares
3 - Anchiano Therapeutics Ltd. (0001534248) (Issuer)
1871dSEC
SEC Form 10-K filed
10-K - Anchiano Therapeutics Ltd. (0001534248) (Filer)
1871dSEC
SEC Form 425 filed
425 - Anchiano Therapeutics Ltd. (0001534248) (Subject)
1896dSEC
SEC Form 424B3 filed
424B3 - Anchiano Therapeutics Ltd. (0001534248) (Filer)
1897dSEC
SEC Form EFFECT filed
EFFECT - Anchiano Therapeutics Ltd. (0001534248) (Filer)
1898dSEC
SEC Form S-4/A filed
S-4/A - Anchiano Therapeutics Ltd. (0001534248) (Filer)
1900dSEC
SEC Form 8-K filed
8-K - Anchiano Therapeutics Ltd. (0001534248) (Filer)
1900dSEC
SEC Form 425 filed
425 - Anchiano Therapeutics Ltd. (0001534248) (Subject)
1906dSEC
SEC Form 425 filed
425 - Anchiano Therapeutics Ltd. (0001534248) (Subject)
1926dSEC
SEC Form S-4 filed
S-4 - Anchiano Therapeutics Ltd. (0001534248) (Filer)
1928dSEC
SEC Form 425 filed
425 - Anchiano Therapeutics Ltd. (0001534248) (Subject)
1934dSEC
SEC Form 425 filed
425 - Anchiano Therapeutics Ltd. (0001534248) (Subject)
1949dSEC
SEC Form S filed
SC 13D/A - Anchiano Therapeutics Ltd. (0001534248) (Subject)
1955dPR
Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement
Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a preclinical biopharmaceutical company, and Chemomab Ltd. (“Chemomab”), a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis